<DOC>
	<DOCNO>NCT02518451</DOCNO>
	<brief_summary>This randomize , single-blind , two-period , two sequence cross-over study fast condition , one-week wash-out period , compare pharmacokinetic profile bioavailability two formulation ( test reference ) valsartan 160 mg film-coated caplets .</brief_summary>
	<brief_title>Bioequivalence Evaluation Two Film-Coated Formulations Valsartan 160 mg</brief_title>
	<detailed_description>In first period , subject receive either test formulation ( 160 mg valsartan film-coated caplets produce PT Dexa Medica , Palembang , Indonesia ) daily , innovator film-coated tablet ( DiovanÂ® 160 , Novartis Farmaceutica S.A. , Barbera del Valles , Spain Novartis Pharma AG , Basel , Switzerland ) daily reference formulation . In subsequent period , one-week wash-out period , received alternate drug . At night start study , subject instruct fast food drink mineral water 9 hour drug administration . In morning , dose day , 48 subject swallow ( without chew ) one dose valsartan 160 mg test formulation reference formulation , 200 mL water . As much 5 mL blood sample drug assay drawn subject , 0.5 , 1 , 1.5 , 2 , 2.5 , 3 , 3.5 , 4 , 6 , 9 , 12 , 16 , 24 , 36 , 48 hour dose . The concentration valsartan plasma assay use validated high performance liquid chromatography fluorescence detector ( HPLC-FL ) method . Pharmacokinetic parameter , include area concentration-versus-time curve ( AUC ) time zero time last quatifiable concentration ( 48 hour dose ) ( AUC-t ) , AUC time zero extrapolate infinity ( AUC-inf ) , maximum concentration ( Cmax ) , time reach maximum concentration ( tmax ) , half-life ( t1/2 ) , assess study .</detailed_description>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . Male female subject absence significant disease clinically significant abnormal laboratory value laboratory evaluation , medical history physical examination screening . 2 . Aged 18 55 year inclusive 3 . Preferably nonsmoker smoke less 10 cigarette per day . 4 . Able participate , communicate well investigator willing provide write informed consent participate study . 5 . Body mass index within 18 25 kg/m2 . 6 . Vital sign ( 10 minute rest ) must within follow range : Systolic blood pressure : 110 120 mm Hg Diastolic blood pressure : 70 80 mm Hg Pulse rate : 60 90 bpm 1 . Personal/family history allergy hypersensitivity contraindication valsartan ally drug . 2 . Pregnant lactate woman ( urinary pregnancy test apply woman subject take study drug ) . 3 . Any major illness past 90 day clinically significant ongoing chronic medical illness e.g . congestive heart failure , hepatitis , hypotensive episode , hyperglycemia , etc . 4 . Presence clinically significant abnormal value screen e.g . significant abnormality liver function test ( ALT , alkaline phosphatase , total bilirubin &gt; = 1.5 ULN ) , renal function test ( serum creatinine concentration &gt; 1.4 mg/dL ) , etc . 5 . Positive Hepatitis B surface antigen ( HBsAg ) , antiHCV , antiHIV . 6 . Clinically significant haematology abnormality . 7 . Clinically significant electrocardiogram ( ECG ) abnormality . 8 . Any surgical medical condition ( present history ) might significantly alter absorption , distribution , metabolism excretion study drug , e.g . gastrointestinal disease include gastric duodenal ulcer history gastric surgery . 9 . Past history anaphylaxis angioedema . 10 . History drug alcohol abuse within 12 month prior screen study . 11 . Participation clinical trial within past 90 day calculate last visit . 12 . History bleed coagulative disorder . 13 . History difficulty donate blood difficulty accessibility vein leave right arm . 14 . A donation loss 300 mL ( ) blood within 3 month study 's first dosing day . 15 . Intake prescription nonprescription drug , food supplement herbal medicine within 14 day study 's first dosing day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>antihypertensive</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>formulation</keyword>
	<keyword>pharmakokinetic</keyword>
	<keyword>valsartan</keyword>
	<keyword>subject</keyword>
	<keyword>Fasting condition</keyword>
</DOC>